{"id":"us-sourced-keytruda","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, Keytruda prevents the PD-1/PD-L1 interaction, allowing the immune system to recognize and attack cancer cells. This mechanism is known as immune checkpoint inhibition.","oneSentence":"Keytruda is a monoclonal antibody that blocks the PD-1 receptor, preventing cancer cells from evading the immune system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:29.067Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06687369","phase":"PHASE3","title":"A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)","status":"RECRUITING","sponsor":"mAbxience Research S.L.","startDate":"2024-12-30","conditions":"Non Squamous Non Small Cell Lung Cancer","enrollment":726},{"nctId":"NCT07160335","phase":"PHASE1","title":"A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-09-26","conditions":"Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma","enrollment":174},{"nctId":"NCT06847334","phase":"PHASE3","title":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04-27","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":772}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["pembrolizumab"],"phase":"phase_3","status":"active","brandName":"US-sourced Keytruda®","genericName":"US-sourced Keytruda®","companyName":"Shanghai Henlius Biotech","companyId":"shanghai-henlius-biotech","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}